Locacorten Vioform Ototoxicity Upon Guinea Pig Middle Ear Application
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Locacorten Vioform (Novartis UK) is frequently prescribed forotomycosis. Its component, Clioquinol, also has anti-bacterial properties. Up to this point, itsototoxic potential has not been evaluated. Our objective aims to evaluate Locacorten Vioform’spotential ototoxicity when applied directly to the middle ear cavity. Materials andMethods: We performed an experimental prospective animal study in our animal researchcenter with 20 Hartley guinea pigs divided into 2 groups. The first group (experimental) wastreated with Locacorten Vioform in one ear and with a physiologic saline solution in the other. The second group (positive control) was treated with concentrated gentamycin in one earand physiologic saline in the other. Auditory brainstem response measurements were obtainedbefore and after three sets of injections. Statistics were analyzed using a varianceanalysis with repeated measures. The histological state of cochlear outer hair cells was comparedbetween the two groups using scanning electron microscopy. Results: Average hearingloss in ears treated with Locacorten Vioform was 32.1 dB, compared with a 2.5 dB averageloss in the saline-treated ears. Ears treated with gentamycin lost an average of 33.0 dB. There were clinically and statistically significant differences between the two ears of the guineapigs in both groups (p<0.001). Scanning electron microscopy revealed severe pericochlearand cochlear inflammation and ossification in the Locacorten Vioform-treated ears. Gentamycin caused significant destruction of outer hair cell architecture. Conclusions: LocacortenVioform induces a hearing loss similar to that caused by gentamycin when applieddirectly to the middle ear of a guinea pig model. Electron microscopy indicates a pericochlearand cochlear inflammatory reaction with ossification.
Abstract
Locacorten Vioform (Novartis UK) is frequently prescribed forotomycosis. Its component, Clioquinol, also has anti-bacterial properties. Up to this point, itsototoxic potential has not been evaluated. Our objective aims to evaluate Locacorten Vioform’spotential ototoxicity when applied directly to the middle ear cavity. Materials andMethods: We performed an experimental prospective animal study in our animal researchcenter with 20 Hartley guinea pigs divided into 2 groups. The first group (experimental) wastreated with Locacorten Vioform in one ear and with a physiologic saline solution in the other. The second group (positive control) was treated with concentrated gentamycin in one earand physiologic saline in the other. Auditory brainstem response measurements were obtainedbefore and after three sets of injections. Statistics were analyzed using a varianceanalysis with repeated measures. The histological state of cochlear outer hair cells was comparedbetween the two groups using scanning electron microscopy. Results: Average hearingloss in ears treated with Locacorten Vioform was 32.1 dB, compared with a 2.5 dB averageloss in the saline-treated ears. Ears treated with gentamycin lost an average of 33.0 dB. There were clinically and statistically significant differences between the two ears of the guineapigs in both groups (p<0.001). Scanning electron microscopy revealed severe pericochlearand cochlear inflammation and ossification in the Locacorten Vioform-treated ears. Gentamycin caused significant destruction of outer hair cell architecture. Conclusions: LocacortenVioform induces a hearing loss similar to that caused by gentamycin when applieddirectly to the middle ear of a guinea pig model. Electron microscopy indicates a pericochlearand cochlear inflammatory reaction with ossification.
참고문헌 (16)
- Munguia R, "Ototopical antifungals and otomycosis: a review", Int J Pediatr Otorhinolaryngol, 72, pp.453~459 (2008)[DOI]
- Martin TJ, "Fungal causes of otitis externa and tympanostomy tube otorrhea", Int J Pediatr Otorhinolaryngol, 69, pp.1503~1508 (2005)[DOI]
- Jinn TH, "Determination of ototoxicity of common otic drops using isolated cochlear outer hair cells", Laryngoscope, 111, pp.2105~2108 (2001)[DOI]
- Tom LW, "Ototoxicity of common topical antimycotic preparations", Laryngoscope, 110, pp.509~516 (2000)[DOI]
- Baylancicek S, "Ototoxic effect of topical ciclopirox as an antimycotic preparation", Otol Neurotol, 29, pp.910~913 (2008)[DOI]
- Marsh RR, "Ototoxicity of antimycotics", Otolaryngol Head Neck Surg, 100, pp.134~136 (1989)[DOI]
- Woods O, "Effect of nystatin on guinea pigs' inner ear", Neurotox Res, 20, pp.301~306 (2011)[DOI]
- Bareggi SR, "Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders", CNS Neurosci Ther, 18, pp.41~46 (2012)[DOI]
- Soltermann W, "Locacorten-vioform in dermatological practice", Praxis, 55, pp.1194~1197 (1966)
- Kohn D, "Anesthesia and analgesia in laboratory animals", pp.172~ (1997), Academic Press
- Snedecor GW, "Statistical methods" (1989), Iowa State University Press
- Mgbor N, "Otomycosis in Nigeria: treatment with mercurochrome", Mycoses, 44, pp.395~397 (2001)[DOI]
- Than KM, "Otomycosis in Burma, and its treatment", Am J Trop Med Hyg, 29, pp.620~623 (1980)[DOI]
- List RJ, "Tympanoplasty graft preparation using ear drops containing polyethylene glycol, flumethasone and clioquinol", J Laryngol Otol, 125, pp.853~855 (2011)[DOI]
- Prezant TR, "Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness", Nat Genet, 4, pp.289~294 (1993)[DOI]
- Heffner R, "Behavioral measurements of absolute and frequency-difference thresholds in guinea pig", J Acoust Soc Am, 49, pp.1888~1895 (1971)[DOI]